



Consommation
et Corporations Canada

Consumer and
Corporate Affairs Canada

Bureau des brevets

Patent Office

Ottawa, Canada
K1A 0C9

(21) (A1)

2,073,326

(22)

1992/07/07

(43)

1993/01/09

5,024,9/79

(51) INTL.CL. ⁵ A61K-031/35; A23L-001/307

(19) (CA) **APPLICATION FOR CANADIAN PATENT** (12)

(54) Method of Inhibiting Sucrase Activity

(72) Hara, Yukihiro - Japan ;
Honda, Miwa - Japan ;

(73) Mitsui Norin Co., Ltd. - Japan ;

(30) (JP) 192694/1991 1991/07/08

(57) 15 Claims

Notice: The specification contained herein as filed

Canada

CCA 3254 (10-89) 41

FIELD OF THE INVENTION

The present invention relates to a sucrase inhibitor which acts specifically on sucrase to thereby inhibit the activity thereof.

BACKGROUND OF THE INVENTION

In this over-indulgent age we live in, obesity and other related diseases which afflict many adults, are serious social problems, and dieting is considered to be an important means of preventing such illnesses.

Sucrase is a digestive enzyme existing in the mucous membrane of the human small intestine and it functions to hydrolyze sucrose into D-glucose and D-fructose. The inhibition of sucrase has strong implications for use in obesity and diabetes cases where it may be used to combat the effects of overeating, and to counteract the effect of moderate sucrose intake in diabetes. To date, various sucrase activity inhibitors have been developed, but they have not been found to be sufficiently effective and many of them often have the added risk of harmful side effects. Therefore the development of a drug which will inhibit the activity of sucrase and may be used safely without causing any harmful side effects, is highly desirable.

SUMMARY OF THE INVENTION

Various research conducted in order to find a natural inhibitor rather than one produced from synthesized chemicals, resulted in the discovery that substances contained in tea are effective inhibitors of sucrase. On the basis of this finding, the present invention was achieved.

The present invention relates to a composition for inhibiting an activity of a sucrase to prevent or treat corpulence while satisfying appetite or to counteract the effect of moderate sucrase intake in diabetics, which composition comprises:

[A] at least one tea polyphenol selected from the group consisting of epigallocatechin gallate, epicatechin gallate, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate in an amount effective to inhibit the activity of the sucrase thereby inhibiting the production of D-glucose and D-fructose, and

[B] a food or a medicinally acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows time-dependent variation of plasma glucose concentration in Example 2.

Figure 2 shows time-dependent variation of insulin concentration in blood in Example 2.

Figure 3 shows time-dependent variation of plasma glucose concentration in Example 4, comparing Polyphenon* 100 with instant green tea (IGT).

Figure 4 shows time-dependent variation of plasma

*Trade-mark

2073326


73299-15

glucose concentration in Example 4, comparing Polyphenon* 100 with instant black tea (IBT).


DETAILED DESCRIPTION OF THE INVENTION

Tea polyphenols which are the active ingredients of the sucrase activity inhibitor of the present invention, include tea catechins of the following general formula (1) and theaflavins of the following general formula (2).

*Trade-mark




where R^1 represents H or OH; and R^2 represents H or





Examples of catechins of the formula (1) are as follows:

- (-) Epicatechin (in formula (1), $R^1=H$, $R^2=H$)
- (-) Epigallocatechin (in formula (1), $R^1=OH$, $R^2=H$)
- (-) Epicatechin Gallate (in formula (1), $R^1=H$, $R^2=$




- (-) Epigallocatechin Gallate (in formula (1), $R^1=OH$, $R^2=$





where R^3 and R^4 each represent H or




and R^3 and R^4 may be the same as or different from each other.

Examples of theaflavins of formula (2) are as follows:


Free Theaflavin (in formula (2), $R^3=H$, $R^4=H$)

Theaflavin Monogallate A (in formula (2), $R^3=$




$R^4=H$)


Theaflavin Monogallate B (in formula (2), $R^3=H$, $R^4=$



Theaflavin Digallate (in formula (2), $R^3=$



$R^4=$



The above-mentioned tea polyphenols can be produced from raw tea leaves, and the method for production is described in U.S. Patent Nos. 4,613,672, 4,673,530 and 4,913,909.

The sucrase activity inhibitor of the present invention can be used in various forms. A suitable amount of the active ingredient, tea polyphenol, may be used singly or it may be dissolved in solvents such as water or alcohols. It may also be blended with a suitable carrier such as gelatin or sodium alginate. If desired, it can be added to food, etc; either directly or after being dissolved in solvents such as water or alcohols.

Suitable amounts of the sucrase activity inhibitor of the present invention to be used in these various ways has been determined. For instance, when it is taken in a medicinal form, from approximately 0.1-10g should be administered perorally, preferably from approximately 0.3 to 5g a day. For peroral administration, the active ingredient of the tea polyphenols may be

taken directly or it may be blended with a carrier and a diluting agent into powdery, granular or capsule preparations. The intake of tea polyphenols should be such that their concentration in the digestive tubes of the human body is from 0.02mM to 2mM, more preferably from 0.1mM to 1mM.

The sucrase activity inhibitor of the present invention may be used as an additive in food etc; for example, it may be added to various food products such as bread, cereal, noodles and other processed products of rice, potato and corn as well as cakes, biscuits, cookies and confectionery during the manufacturing process, in an amount from 0.01 to 2.0%, or preferably from 0.1 to 1.0%.

The present invention will be explained in more detail by way of the following examples, which, however are not intended to restrict the scope of the invention.

EXAMPLE 1

Sucrase was prepared from the mucous membrane of the small intestines of Wistar rats in accordance with Dahlquist's Method (A. Dahlquist, Anal. Biochem., 7, 18 (1964)).

50 μ l of a sample and 100 μ l of a substrate solution (substrate: 60mM sucrose solution) were added to 50 μ l of an enzyme solution (221 U/ml buffer) and were reacted at 37 °C for 15 minutes. Then the absorbance of the sugar formed by the reaction was measured at 540nm by Bernfeld's method (P. Bernfeld, Meth. Enzymol., 1, 49 (1959)). The value thus

measured was converted into the amount of decomposed sucrose, and the reaction speed was calculated using a standard method. The reaction speed of the control case (where distilled water was added instead of the sample solution) was also obtained in the same manner. Sucrase activity in the control case was calculated to be 100%. Samples, each in a final concentration of 5×10^{-4} M, and the inhibition (percentage) of the activity was obtained. The results are shown in Table 1.

Table 1

Sample	Inhibition (%)
Gallic Acid	6.7
(+)Catechin	13.7
Epicatechin	14.7
Epigallocatechin	17.3
Epicatechin Gallate	62.5
Epigallocatechin Gallate	78.8
Free Theaflavin	6.8
Theaflavin Monogallate A	45.9
Theaflavin Monogallate B	59.5
Theaflavin Digallate	95.9

It was confirmed that out of the catechins and theaflavins tested, epicatechin, epigallocatechin and free theaflavin had only slight sucrase activity inhibiting capacity, but the remaining catechins and theaflavins had strong sucrase activity inhibiting capacity (Table 1).

EXAMPLE 2

Wistar rats (6 weeks old) were divided into two groups. Rats of one group (control) were fed with water only, while 1ml of

an aqueous solution (80 mg/ml) containing crude catechins (Polyphenon 100, product of Mitsui Norin Co. Ltd., the composition of the product is shown in Table 2 below) was perorally administered to each rat of the other group (test group). The plasma glucose level and plasma insulin concentration in the test animals was measured at determined intervals by a mutase/GTO method and a one-step enzyme immunoassay method. The results are shown in Fig. 1 and Fig. 2. As is obvious from these graphs, elevation of the blood glucose level was significantly inhibited when catechins were administered to the test animals before the administration of sucrose. It was also confirmed that the blood insulin concentration decreased. From these facts, it was obvious that the absorbance of glucose decreased due to the sucrase inhibiting activity of catechins and that the blood glucose level and blood insulin concentration was consequently reduced.

Table 2
Composition of Polyphenon 100

Constitutive Components(tea catechins)	Absolute Propotion(%)	Relative Propotion(%)
Gallocatechin	1.44	1.6
Epigallocatechin	17.57	19.3
Catechin	-	-
Epicatechin	5.81	6.4
Epigallocatechin Gallate	59.3	59.1
Epicatechin Gallate	12.51	13.7

EXAMPLE 3

An acute toxicity test of the sucrase activity inhibitor of the present invention was carried out using male ICR mice. LD₅₀ was calculated by the Van der Waerden method. The results obtained are shown in Table 3 below.

Table 3

Components	LD ₅₀ (reliable limit) mg/kg	
	peroral administration	intraabdominal administration
Crude Catechin(*)	2412	-
Crude Theaflavin(**)	-	55.2
Epigallocatechin Gallate	-	150

(*) Composition of crude catechin:see Table 2 above

(**) Composition of crude theaflavin:see Table 4 below

Table 4

Free Theaflavin	10.0 (%)
Theaflavin Monogallate A	22.3
Theaflavin Monogallate B	19.5
Theaflavin Digallate	32.5
(+)Catechin	0.3
(-)Epicatechin	1.8
(-)Epigallocatechin Gallate	4.7
(-)Epigallocatechin Gallate Isomer	1.0
(-)Epicatechin Gallate	3.9
Others(Theaflavin Isomers,etc.)	4.0

The tolerance level is usually considered to be 1/3 of the LD₅₀. In this case as compared to the LD₅₀ only a very small amount of the sucrase activity inhibitor (0.1-10g) is necessary to obtain sufficient sucrase activity inhibiting effect. Therefore the sucrase activity inhibitor of the present invention is very safe

and it may be used not only for medicinal purposes, but also as an additive to food, without fear of harmful side effects to the human body.

Example 4

The effect of instant green tea (IGT) and instant black tea (IBT) on the glucose concentration in the blood of rats administered sucrose was studied and no significant differences were found as compared with the control (Figs. 3 and 4). At a concentration of 10mg, corresponding to about 6 cups of tea a day for humans, there were no significant differences in the blood glucose level. From these results it is clear that merely drinking tea, at an average of 6 cups a day, will not reduce the blood glucose level.

Thus, the sucrase activity inhibitor of the present invention is extremely useful for inhibition of sucrase activity in the human body.

2073326

73299-15

The sucrase activity inhibitor of the present invention either in a medicine form or a food form is usually put in a container. The container may bear instructions or suggestions that the compositions can be taken for preventing or treating obesity or diabeties.

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A composition for inhibiting an activity of a sucrase to prevent or treat corpulence while satisfying appetite or to counteract the effect of moderate sucrose intake in diabetics, which composition comprises:

[A] at least one tea polyphenol selected from the group consisting of epigallocatechin gallate, epicatechin gallate, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate in an amount effective to inhibit the activity of the sucrase thereby inhibiting the production of D-glucose and D-fructose, and

[B] a food or a medicinally acceptable carrier.

2. The composition as claimed in claim 1, wherein the tea polyphenol is epigallocatechin gallate.

3. The composition as claimed in claim 1, wherein the tea polyphenol is epicatechin gallate.

4. The composition as claimed in claim 1, wherein the tea polyphenol is theaflavin monogallate A.

5. The composition as claimed in claim 1, wherein the tea polyphenol is theaflavin monogallate B.

6. The composition as claimed in claim 1, wherein the tea polyphenol is theaflavin digallate.

7. The composition as claimed in claim 1, which is a medicine containing [A] the tea polyphenol in such an amount that

0.1-10g of the tea polyphenol is administered per day perorally and [B] a medicinally acceptable carrier.

8. The composition as claimed in claim 7, wherein the amount is 0.3-5g per day.

9. The composition as claimed in claim 1, which is food containing 0.01 to 2.0% by weight of the food.

10. The composition as claimed in claim 9, wherein the food is bread, cereal, noodle, cake, biscuit or cookie.

11. The composition as claimed in any one of claims 1 to 6, 9 or 10, which is placed in a container bearing instructions that the composition may be used for treating or preventing obesity or diabetes.

12. The medicine as claimed in claim 7 or 8, which is in a container bearing instructions that the medicine may be used for treating or preventing obesity or diabetes.

13. A use of at least one tea polyphenol selected from the group consisting of epigallocatechin gallate, epicatechin gallate, theaflavin monogallate A, theaflavin monogallate B and theaflavin digallate in an amount effective to inhibit the activity of the sucrase thereby inhibiting the production of D-glucose and D-fructose, for preventing or treating obesity or diabetes.

14. The use as claimed in claim 13, for preventing or

2073326
73299-15

treating obesity.

15. The use as claimed in claim 13, for treating
diabetics.

SMART & BIGGAR
OTTAWA, CANADA
PATENT AGENTS

FIG.1






FIG.2




Patent Agents
Smart & Biggar

FIG. 3



a : $p < 0.05$ to control

FIG. 4



a : $p < 0.05$ to control

Patent Agents
Smart & Rogers